EP Patent

EP4665344A1 — Lumateperone and derivatives thereof for modulating the nervous system

Assigned to Intra Cellular Therapies Inc · Expires 2025-12-24 · 0y expired

What this patent protects

The present disclosure relates to use of Compounds of Formula (I), Compounds of Formula (II), and related analogs, for enhancing neuritogenesis, enhancing neurite outgrowth, enhancing neural growth, neural connectivity, synaptic density, dendritic spine density, dendritic spine s…

USPTO Abstract

The present disclosure relates to use of Compounds of Formula (I), Compounds of Formula (II), and related analogs, for enhancing neuritogenesis, enhancing neurite outgrowth, enhancing neural growth, neural connectivity, synaptic density, dendritic spine density, dendritic spine size, and excitatory neurotransmission, in the brain (e.g., in the medial prefrontal cortex), and other methods and uses related thereto.

Drugs covered by this patent

Patent Metadata

Patent number
EP4665344A1
Jurisdiction
EP
Classification
Expires
2025-12-24
Drug substance claim
No
Drug product claim
No
Assignee
Intra Cellular Therapies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.